ANTI-TAA/ANTI-CD3 MULTISPECIFIC ANTIBODY

The present invention addresses the problem of providing an anti-TAA/anti-CD3 multispecific antibody that can be used in treatment of humans.　In order to produce an anti-TAA/anti-CD3 multispecific antibody that targets various tumor associated antigens (TAAs), the inventors of the present invention...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHAEN, Takashi, YAGI, Shigenori, SATAKE, Yoshiki, SOGA, Shinji, SATO, Masahito, HONDA, Takashi
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention addresses the problem of providing an anti-TAA/anti-CD3 multispecific antibody that can be used in treatment of humans.　In order to produce an anti-TAA/anti-CD3 multispecific antibody that targets various tumor associated antigens (TAAs), the inventors of the present invention used their company's protein structure information analysis techniques and known information regarding anti-CD3 scFv, and obtained 16 types of anti-CD3 scFv which have affinity to various CD3 and improved stability. Furthermore, a multispecific antibody combining a plurality of anti-TAA antibodies for TSPAN8, CD37, etc. was produced, and it was confirmed that the obtained multispecific antibody maintained various binding activity to CD3 and stability.　Thus, the obtained 16 types of anti-CD3 scFv can be used in producing an anti-TAA/anti-CD3 multispecific antibody for an arbitrary TAA.